These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 18240539)

  • 1. Osteoporosis and inflammation.
    Mundy GR
    Nutr Rev; 2007 Dec; 65(12 Pt 2):S147-51. PubMed ID: 18240539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
    Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
    Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies.
    Tyagi AM; Mansoori MN; Srivastava K; Khan MP; Kureel J; Dixit M; Shukla P; Trivedi R; Chattopadhyay N; Singh D
    J Bone Miner Res; 2014 Sep; 29(9):1981-92. PubMed ID: 24677326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytokines in bone diseases. Cytokine and postmenopausal osteoporosis].
    Inada M; Miyaura C
    Clin Calcium; 2010 Oct; 20(10):1467-72. PubMed ID: 20890027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis.
    D'Amelio P; Grimaldi A; Di Bella S; Brianza SZM; Cristofaro MA; Tamone C; Giribaldi G; Ulliers D; Pescarmona GP; Isaia G
    Bone; 2008 Jul; 43(1):92-100. PubMed ID: 18407820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin and inflammation.
    Saidenberg Kermanac'h N; Bessis N; Cohen-Solal M; De Vernejoul MC; Boissier MC
    Eur Cytokine Netw; 2002; 13(2):144-53. PubMed ID: 12101070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
    Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
    Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of cytokines in inflammatory bone loss.
    Souza PP; Lerner UH
    Immunol Invest; 2013; 42(7):555-622. PubMed ID: 24004059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
    Hofbauer LC; Schoppet M
    JAMA; 2004 Jul; 292(4):490-5. PubMed ID: 15280347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines.
    Naidu VG; Dinesh Babu KR; Thwin MM; Satish RL; Kumar PV; Gopalakrishnakone P
    Chem Biol Interact; 2013 Apr; 203(2):467-79. PubMed ID: 23333834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ablation of p38α MAPK Signaling in Osteoblast Lineage Cells Protects Mice From Bone Loss Induced by Estrogen Deficiency.
    Thouverey C; Caverzasio J
    Endocrinology; 2015 Dec; 156(12):4377-87. PubMed ID: 26441240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of sex hormones on bone metabolism of the otic capsule--an overview.
    Horner KC
    Hear Res; 2009 Jun; 252(1-2):56-60. PubMed ID: 19121641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of RANKL by peripheral neutrophils and its association with bone mineral density in COPD.
    Hu X; Sun Y; Xu W; Lin T; Zeng H
    Respirology; 2017 Jan; 22(1):126-132. PubMed ID: 27552066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.
    Morabito N; Gaudio A; Lasco A; Atteritano M; Pizzoleo MA; Cincotta M; La Rosa M; Guarino R; Meo A; Frisina N
    J Bone Miner Res; 2004 May; 19(5):722-7. PubMed ID: 15068494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
    Mera K; Ito K
    Clin Calcium; 2007 Jan; 17(1):37-46. PubMed ID: 17211092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total Saponin from Anemone flaccida Fr. Schmidt Prevents Bone Destruction in Experimental Rheumatoid Arthritis via Inhibiting Osteoclastogenesis.
    Liu C; Yang Y; Sun D; Wang C; Wang H; Jia S; Liu L; Lin N
    Rejuvenation Res; 2015 Dec; 18(6):528-42. PubMed ID: 26418168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.